Navigation Links
Einstein College of Medicine receives $5.7 million for developmental disabilities research
Date:10/17/2011

October 17, 2011 (BRONX, NY) The Eunice Kennedy Shriver National Institute for Child Health and Human Development, part of the National Institutes of Health, has awarded researchers at Albert Einstein College of Medicine of Yeshiva University $5.7 million to fund the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center (IDDRC). The grant supports Einstein's ongoing efforts to improve the lives of children with intellectual and developmental disabilities (IDD) through combined basic science research and clinical practice.

Occurring in an estimated 10 percent of the population, IDDs constitute some of the most significant health conditions in children. They represent a diverse group of chronic conditions such as autism spectrum disorders and Down syndrome that can limit daily function and impede mobility, language and more. IDDs can begin anytime during a child's development up to 22 years of age, and usually last a lifetime.

"The Rose F. Kennedy Center was founded more than 40 years ago as one of the nation's flagship centers on mental retardation," said Steven Walkley, D.V.M., Ph.D., director of Einstein's IDDRC and professor in the Dominick P. Purpura Department of Neuroscience. "This grant allows us to intensify the translational research we've been doing, which when coupled with clinical care, may lead to a better understanding of the causes, consequences and potential treatments of these conditions." Dr. Walkley is also professor of pathology and in the Saul R. Korey Department of Neurology. John Foxe, Ph.D., director of research at Einstein's Children's Evaluation and Rehabilitation Center (CERC), will serve as the center's associate director.

Einstein's IDDRC is an interdisciplinary collaboration involving numerous academic departments including neuroscience, genetics, neurology and pediatrics along with the Gruss Magnetic Resonance Research Center and CERC, which is directed by Robert Marion, M.D., the Ruth L. Gottesman Professor of Developmental Pediatrics. Its six scientific cores are designed to provide the means for human and animal phenotyping, neuron and whole brain imaging, cell and tissue manipulation, and genetic analysis.

There will be four main areas of focus for the IDDRC that draw on Einstein's strengths in basic science research and extensive clinical practice. The themes are autism spectrum disorders, neurogenetic and seizure disorders, nutritional and environmental determinants of brain development, and deafness and communication disorders.

"While tremendous strides have been made over the past four decades to identify and treat these disorders, it is critical to leverage the most recent advances in research and technologies to better understand what causes them and provide more targeted and effective therapies," explained Dr. Walkley. "Through the combined efforts of our faculty researchers and clinicians, we hope to improve methods of diagnosis, prevention and treatment."

Einstein's IDDRC will also continue to build and sustain outreach programs to help alleviate some of the burden of IDDs on families in the Bronx, which is one of the most ethnically diverse and poorest urban counties in the United States.


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Einstein to utilize electronic medical records system to analyze HIV/AIDS in central Africa
2. Einstein scientists find crucial molecule involved in spread of breast cancer
3. Einstein secures $11 million to continue research on brain aging and Alzheimers disease
4. Einstein Montefiore lung specialist to receive award for work with 9/11 rescue workers
5. Feinstein scientists identify abnormal disease pathway in dystonia
6. Susan Band Horwitz, Ph.D., of Einstein, receives lifetime achievement award in cancer research
7. Einstein-Montefiore researcher will test nanoparticles against pancreatic cancer
8. ALBERT EINSTEIN COLLEGE OF MEDICINE HELPS ADDRESS NEED FOR IMPROVED CANCER CARE IN RURAL AMERICA
9. Feinstein Institute to share $5M US Department of Defense grant
10. Einstein scientist awarded $4 million to develop genetic strategy to combat tuberculosis
11. Einstein awarded NIH grant to study drug-resistant TB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... John Stewart joins Privis ... Member for t4 Leadership Development & Consulting. He has spent his career focusing ... physician leadership development, servant leadership, data driven process improvement, and supportive technology. These ...
(Date:8/21/2017)... (PRWEB) , ... August 22, 2017 , ... ... but not without risk to health and safety. By learning and implementing best ... eliminated. , In this webinar, attendees will gain a better understanding of ...
(Date:8/21/2017)... ... ... Five chefs from local senior assisted living homes will serve Mediterranean-inspired gourmet ... be able to vote for their favorite Chef among the following: , GREECE, Chef ... Cheese Sauce & Garlic Pita Crisp, Greek Mountain Ice Tea , ITALY, Chef Gabriel ...
(Date:8/21/2017)... ... , ... The American Hospital Association (AHA) has elected Claire Zangerle, Chief Nurse ... Board of Trustees for a three-year term beginning January 1, 2018. , The ... that are committed to the improvement of health in their communities. Founded in 1898, ...
(Date:8/20/2017)... ... August 20, 2017 , ... HIPAA Solutions, LC ... has assisted multiple clients in successfully passing audits such as Office of Civil ... (AICPA SOC Level 2), and State Data Use Agreement Audits. , HIPAA ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc ... reached agreements to resolve virtually all known U.S. mesh ... discussions to resolve the known remaining U.S. claims at ... payments beginning in the fourth quarter of 2017 and ... of its second quarter 2017 results, the Company intends ...
(Date:8/4/2017)... CINCINNATI , Aug. 3, 2017  Agragen, ... science company active in the biopharmaceutical, nutraceutical, and ... its development of its lead drug candidates, AGR131.  ... a proinflammatory cytokine from the blood of patients ... psoriasis, and inflammatory bowel disease. ...
Breaking Medicine Technology: